Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005 Donald R. VanDevanter, Eric P. Elkin,

Slides:

Advertisements

Similar presentations

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Advertisements

IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis Donald.

Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations

Donald R. VanDevanter, David J. Pasta, Michael W. Konstan

The prevalence of “risky behaviour” in adults with cystic fibrosis

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis Cori Daines, Donald VanDeVanter,

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation.

P. Whitaker, N. Shaw, J. Gooi, C. Etherington, S. Conway, D. Peckham

Is infection with hypermutable Pseudomonas aeruginosa clinically significant? Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir

Sweat conductivity: An accurate diagnostic test for cystic fibrosis?

HbA1c as a screening tool for cystic fibrosis related diabetes

Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation.

Complications of long and intermediate term venous catheters in cystic fibrosis patients: A multicenter study Teresa L. May, Alex H. Gifford, Thomas.

Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Nadav Traeger, Qiuhu Shi, Allen J. Dozor Journal of Cystic Fibrosis

Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint D.R. VanDevanter, A. Yegin, W.J. Morgan,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

The ease of breathing test tracks clinical changes in cystic fibrosis

Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis T.W.V. Daniels, G.B. Rogers, F.A. Stressmann, C.J.

Pulmonary exacerbations in CF patients with early lung disease

The applicability of urinary creatinine as a method of specimen normalization in the cystic fibrosis population Brandie D. Wagner, Frank J. Accurso,

Controlled clinical trials in cystic fibrosis — are we doing better?

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Cystic fibrosis mortality trend in Italy from 1970 to 2011

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation.

Pulmonary nocardiosis in cystic fibrosis

A.H. Gifford Journal of Cystic Fibrosis

Demographics of glucose metabolism in cystic fibrosis

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Physiologic endpoints for clinical studies for cystic fibrosis

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis

Nasal polyposis in lung transplant recipients with cystic fibrosis

Elliott C. Dasenbrook, Gregory S. Sawicki Journal of Cystic Fibrosis

D.Y.F. Mak, J. Sykes, A.L. Stephenson, L.C. Lands

Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint M.W. Konstan, J.S. Wagener, A. Yegin, S.J.

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale

Disease disclosure in individuals with cystic fibrosis: Association with psychosocial and health outcomes Adrienne P. Borschuk, Robin S. Everhart, Michelle.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis M.N. Hurley, A.H. Amin Ariff, C. Bertenshaw,

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis Cori Daines, Donald VanDeVanter,

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

Michael W. Konstan, David J. Pasta, Jeffrey S. Wagener, Donald R

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis Malena Cohen-Cymberknoh, Hannah Blau, David Shoseyov,

CFTR modulators and pregnancy: Our work has only just begun

Felix Ratjen, Todd Durham, Tomas Navratil, Amy Schaberg, Frank J

Michael W. Konstan, Jeffrey S. Wagener, Donald R. VanDevanter, David J

Patients with cystic fibrosis and normoglycemia exhibit diabetic glucose tolerance during pulmonary exacerbation Noa Nezer M. Sc, David Shoseyov, Eitan.

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005 Donald R. VanDevanter, Eric P. Elkin, David J. Pasta, Wayne J. Morgan, Michael W. Konstan Journal of Cystic Fibrosis Volume 12, Issue 4, Pages 332-337 (July 2013) DOI: 10.1016/j.jcf.2012.11.011 Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Average annual incidence of antibiotic treatment events associated with pulmonary exacerbations from 1995–2005 by administration route and age group. Panel A, average incidence of all antibiotic treatment events. Panel B, incidence of antibiotic treatment events not including IV antibiotics. Panel C, incidence of antibiotic treatment events in which IV antibiotics were included. Open circles with gray dashed lines, patients less than 6years of age. Light gray circles with black dashed lines, patients 6 to 12years of age. Dark gray circles with solid gray line, patients 13 to 17years of age. Black circles with black lines, patients 18years of age and older. Note that vertical axes for Panels B and C differ from that of Panel A. Journal of Cystic Fibrosis 2013 12, 332-337DOI: (10.1016/j.jcf.2012.11.011) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Distributions of modified Rabin scores and mean annual differences in mean modified Rabin scores for evaluable IV and non-IV treatment events by age group. Clear bars, antibiotic treatments not including IV antibiotics. Black bars, treatments including IV antibiotics. Panel A, mean modified Rabin clinical scores associated with pulmonary exacerbation treatment events between 1995 and 2005 by route of administration and age group. Possible scores range from 0 to 4. Bars show 95% confidence intervals for means. Panel B, distributions of treatment-associated modified Rabin scores between 1995 and 2005 by route of administration. Journal of Cystic Fibrosis 2013 12, 332-337DOI: (10.1016/j.jcf.2012.11.011) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Average modified Rabin clinical scores associated with pulmonary exacerbations from 1995–2005 by antibiotic administration route and age group. Panel A, modified Rabin scores associated with antibiotic treatment events not including IV antibiotics. Panel B, modified Rabin scores associated with antibiotic treatment events in which IV antibiotics were included. Open circles with gray dashed lines, patients less than 6years of age. Light gray circles with black dashed lines, patients 6 to 12years of age. Dark gray circles with solid gray line, patients 13 to 17years of age. Black circles with black lines, patients 18years of age and older. Journal of Cystic Fibrosis 2013 12, 332-337DOI: (10.1016/j.jcf.2012.11.011) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions